A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumours in half of women with the disease.

Researchers believe the drug, which mimics the action of folic acid to enter cells, could hold huge promise for women with advanced ovarian cancer who have stopped responding to standard treatment.

A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug, known in the study as ONX-0801, in 15 women with ovarian cancer as part of a wider phase I clinical trial.

But in the new study, which is still ongoing, ONX-0801 significantly shrunk tumours in seven of the 15 ovarian cancer patients – results the researchers described as ‘exciting’ and ‘very promising’.

And in patients whose tumours had the particular molecular target for the drug, the results were even better – with seven of 10 women responding.

The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago.

ONX-0801 is the first in a brand new class of drugs, discovered at the ICR, which attacks ovarian cancer by mimicking folic acid to enter cancer cells. The drug kills cells by blocking a molecule called thymidylate synthase and causing irreparable DNA damage.

Because ovarian cancer cells have an abnormally large number of receptors for folic acid, called alpha folate receptors, they are particularly targeted by the treatment, while healthy cells are left alone.

And the trial found that because the drug targets cancer cells specifically, it did not have side-effects often seen with traditional chemotherapy such as infections, diarrhoea, nerve damage and hair loss.

The researchers have also identified tests that detect tumours with high levels of the alpha folate receptor, so that doctors can pick out the women most likely to benefit from the treatment.

The ICR and Royal Marsden team, alongside partners at specialist healthcare company BTG, is looking for partners to fund next-stage clinical trials as soon as possible – to see whether the drug can have the hoped-for benefits for survival for patients with ovarian cancer and other cancers.

The trial was conducted in collaboration with Onyx Pharmaceuticals, Inc., now a subsidiary of Amgen Inc., and received funding from BTG.

The drug, which will be known as BTG945 going forward, will also be highlighted at ASCO by the UK’s Department for International Trade, as one of the UK’s best biopharma assets available for licensing or partnering.

Study leader Dr Udai Banerji, Deputy Director of the Drug Development Unit at the ICR and The Royal Marsden, said “The results we have seen in this trial are very promising. It is rare to see such clear evidence of reproducible responses in these early stages of drug development. The beauty of this particular drug is that it is targeted to the cancer cell. This means there are fewer side-effects, making it a kinder treatment for ovarian cancer patients. It’s early days of course, but I’m keen to see this treatment assessed in later-stage clinical trials as soon as possible. We have also developed tests to pick out the women who are likely to respond to the drug, making the treatment potentially more cost-effective, and ensuring other patients can receive alternative treatment.”

Professor Paul Workman, Chief Executive of the ICR, said: “It’s really exciting to see such positive results in an early-stage trial. ONX-0801 is the latest in a long line of precision cancer medicines to have been discovered here at the ICR – 20 since 2005 alone. The drug works in a particularly clever way by mimicking the effects of folic acid to hit cancer cells selectively while leaving healthy tissue alone. It looks a highly promising treatment with the potential to have huge benefits for women with ovarian cancer, and I’m very keen to see it progress to later-stage trials.”

Source: ICR